IR@PKUHSC  > 北京大学第三临床医学院  > 肿瘤放疗科
学科主题临床医学
Image-Guided Percutaneous I-125 Seed Implantation as a Salvage Treatment for Recurrent Soft Tissue Sarcomas After Surgery and Radiotherapy
Li, Jinna1; Wang, Junjie1; Meng, Na1; Qu, Ang1; Yuan, Huishu2; Liu, Chen2; Ran, Weiqiang3; Jiang, Yuliang1
关键词Ct I-125 Seed Implantation Radiotherapy Recurrent Soft Tissue Sarcoma Surgery Ultrasound Outcome
刊名CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
2011-02-01
DOI10.1089/cbr.2010.0847
26期:1页:113-120
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Medicine, Research & Experimental ; Pharmacology & Pharmacy ; Radiology, Nuclear Medicine & Medical Imaging
研究领域[WOS]Oncology ; Research & Experimental Medicine ; Pharmacology & Pharmacy ; Radiology, Nuclear Medicine & Medical Imaging
关键词[WOS]EXTERNAL-BEAM RADIOTHERAPY ; FUNCTION-SAVING RESECTION ; RADIATION-THERAPY ; WOUND COMPLICATIONS ; INTRAOPERATIVE BRACHYTHERAPY ; INTERSTITIAL BRACHYTHERAPY ; ADJUVANT BRACHYTHERAPY ; SURGICAL RESECTION ; RANDOMIZED-TRIAL ; LOCAL-CONTROL
英文摘要

The purpose of this study was to evaluate the safety and efficacy of percutaneous iodine-125 (I-125) seed implantation using computed tomography (CT) or ultrasound guidance in the treatment of recurrent soft tissue malignancies after surgery and radiotherapy. From February 2002 to September 2009, 18 patients with recurrent soft tissue sarcomas were treated under ultrasound or CT guidance. The actuarial median number of I-125 seeds implanted was 35 (range, 6-129), and the actuarial D90 of the implanted I-125 seeds ranged from 107.9 to 204.4 Gy (median, 147.1 Gy). The activity of the seeds ranged from 0.4 to 0.8 mCi (median, 0.7mCi). Follow-up times ranged from 4 to 78 months (median, 20 months). The median local control was 41 months (95% CI, 15.9-66.1 months). The 1-, 2-, 3-, 4-, and 5-year local controls were 78.8%, 78.8%, 78.8%, 26.3%, and 0%, respectively. The median survival was 32 months (95% CI, 16-48 months). The actuarial 1-, 2-, 3-, 4-, and 5-year survivals were 76.6%, 61.3%, 39.4%, 39.4%, and 39.4%, respectively. Seven (7) patients (38.9%) experienced recurrence after seed implantation. Six (6) patients (33.3%) died of distant metastases and 1 died of stroke. Two (2) patients developed ulceration, 1 case caused by recurrence and another by a reaction of the skin to radiation. Percutaneous I-125 seed implantation for recurrent soft tissue malignancies under CT or ultrasound guidance is safe and is associated with high efficacy and low morbidity.

语种英语
WOS记录号WOS:000287860900008
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56181
专题北京大学第三临床医学院_肿瘤放疗科
北京大学第三临床医学院_肿瘤治疗中心
作者单位1.Peking Univ, Hosp 3, Ctr Canc, Dept Radiat Oncol, Beijing 100191, Peoples R China
2.Peking Univ, Hosp 3, Dept Radiol, Beijing 100191, Peoples R China
3.Peking Univ, Hosp 3, Dept Ultrasound, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Li, Jinna,Wang, Junjie,Meng, Na,et al. Image-Guided Percutaneous I-125 Seed Implantation as a Salvage Treatment for Recurrent Soft Tissue Sarcomas After Surgery and Radiotherapy[J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS,2011,26(1):113-120.
APA Li, Jinna.,Wang, Junjie.,Meng, Na.,Qu, Ang.,Yuan, Huishu.,...&Jiang, Yuliang.(2011).Image-Guided Percutaneous I-125 Seed Implantation as a Salvage Treatment for Recurrent Soft Tissue Sarcomas After Surgery and Radiotherapy.CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS,26(1),113-120.
MLA Li, Jinna,et al."Image-Guided Percutaneous I-125 Seed Implantation as a Salvage Treatment for Recurrent Soft Tissue Sarcomas After Surgery and Radiotherapy".CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 26.1(2011):113-120.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Jinna]的文章
[Wang, Junjie]的文章
[Meng, Na]的文章
百度学术
百度学术中相似的文章
[Li, Jinna]的文章
[Wang, Junjie]的文章
[Meng, Na]的文章
必应学术
必应学术中相似的文章
[Li, Jinna]的文章
[Wang, Junjie]的文章
[Meng, Na]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。